Evidence map›Paper›PMID 41355861›Full record

ArticleRSC medicinal chemistry2026

The structural requirements of 3,5-substituted oxindoles that determine selective AMPK or GSK3β inhibition.

Juliet E Strang, Daniel D Astridge, Caleb Chandler, Vu T Nguyen, Philip Reigan

Abstract read
In one paragraph

Article in RSC medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Juliet E StrangDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus 12850 East Montview Boulevard Aurora CO 80045 USA philip.reigan@cuanschutz.edu +1(303)724 6431.ORCID https://orcid.org/0000-0002-5993-388X
Daniel D AstridgeDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus 12850 East Montview Boulevard Aurora CO 80045 USA philip.reigan@cuanschutz.edu +1(303)724 6431.ORCID https://orcid.org/0000-0002-8504-260X
Caleb ChandlerDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus 12850 East Montview Boulevard Aurora CO 80045 USA philip.reigan@cuanschutz.edu +1(303)724 6431.ORCID https://orcid.org/0000-0002-9687-2801
Vu T NguyenDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus 12850 East Montview Boulevard Aurora CO 80045 USA philip.reigan@cuanschutz.edu +1(303)724 6431.ORCID https://orcid.org/0000-0002-4363-9803
Philip ReiganDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus 12850 East Montview Boulevard Aurora CO 80045 USA philip.reigan@cuanschutz.edu +1(303)724 6431.ORCID https://orcid.org/0000-0003-0346-1016

Funding

Development of AMPK Inhibitors for the treatment of leukemiaR01CA251534 · NCI · UNIVERSITY OF COLORADO DENVER · PI REIGAN, PHILIP · 2021 to 2025
$1.7M
NCI NIH HHS R01 CA251534
6 · The paper itself

Abstract

AMP-activated protein kinase (AMPK) acts as a central cellular sensor at the interface of metabolic and signaling networks, that supports cell survival in energetically unfavorable environments. Due to its role in the direct mediation of fatty acid oxidation

Identifiers

PMID41355861
PMCPMC12679472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.